Hemogenyx Pharmaceuticals PLC Director/PDMR Shareholding (5600R)
09 March 2021 - 6:00PM
UK Regulatory
TIDMHEMO
RNS Number : 5600R
Hemogenyx Pharmaceuticals PLC
09 March 2021
9 March 2021
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Director/PDMR Shareholding
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has
been notified that Andrew Wright, the Company's Financial
Controller and Company Secretary (PDMR), has purchased 94,882
ordinary shares of GBP0.01 each in the Company ("Ordinary Shares")
at an average price of 6.03p per share. Following this transaction,
Mr Wright has a total beneficial interest in 1,626,991 Ordinary
Shares, representing approximately 0.36 per cent of the Company's
issued share capital.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been deemed inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 until the release of this
announcement.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1. Details of PDMR/person closely associated with them
("PCA")
a) Name Andrew Wright
------------------------------ ---------------------------------------------
b) Position/status PDMR: Financial Controller and Company
Secretary
------------------------------ ---------------------------------------------
c) Initial notification/ Initial notification
amendment
------------------------------ ---------------------------------------------
2. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
-----------------------------------------------------------------------------
a) Description of Ordinary shares of Hemogenyx Pharmaceuticals
the financial plc
instrument Identification code GB00BYX3WZ24
------------------------------ ---------------------------------------------
b) Nature of the Standalone acquisition of shares
transaction
------------------------------ ---------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP GBP0.0603 94,882
----------
------------------------------ ---------------------------------------------
d) Aggregated information Price(s) Volume(s)
* Aggregated volume GBP GBP5,721.38 94,882
----------
* Price
------------------------------ ---------------------------------------------
e) Date of the transaction 2021-03-08
------------------------------ ---------------------------------------------
f) Place of the transaction London Stock Exchange
XLON
------------------------------ ---------------------------------------------
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDBGDXGSGDGBI
(END) Dow Jones Newswires
March 09, 2021 02:00 ET (07:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024